All In Biotech

Drug Trial Radar · NCT00171821

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload

Last checked: Nov 20, 2026Latest source record: Feb 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,784

Actual

Start

Apr 2005

Primary completion

May 2009

Study completion Jul 2010

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study uses a single arm, multi-center, open-label trial design. The study will assess the efficacy and safety of 52 weeks of treatment with deferasirox (ICL670) in patients with evidence of transfusion induced iron overload.

Conditions

  • Transfusion-dependent Iron Overload

Interventions

  • DeferasiroxDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate if fixed starting doses of ICL670, based on transfusion history and subsequent dose titration can provide clinically acceptable chelation as measured by serum ferritinTime frame: at baseline and at 52 weeks

Locations

97 sites in 23 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Adelaide, Australia

  • Novartis Investigative Site

    Camperdown, Australia

  • Novartis Investigative Site

    Clayton, Australia

  • Novartis Investigative Site

    Melbourne, Australia

  • Novartis Investigative Site

    Perth, Australia

  • Novartis Investigative Site

    South Brisbane, Australia

  • Novartis Investigative Site

    Westmead, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Godinne, Belgium

  • Novartis Investigative Site

    La Louvière, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Guangzhou, China

  • Novartis Investigative Site

    Nanjing, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Aarhus, Denmark

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Herlev, Denmark

  • Novartis Investigative Site

    Hillerød, Denmark

  • Novartis Investigative Site

    Cairo, Egypt

  • Novartis Investigative Site

    Angers, France

  • Novartis Investigative Site

    Avignon, France

  • Novartis Investigative Site

    Bobigny, France

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pessac, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, France

  • Novartis Investigative Site

    Augsburg, Germany

  • Novartis Investigative Site

    Braunschweig, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Düsseldorf, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.